Current literature suggests that genetic mutations and polymorphisms, as well as epigenetic changes such as differential methylation and alteration in gene expression, have a role in the outcomes of ovarian cancer [18]. One example of this is the differential overexpression of phosphoserine phosphatase homolog (PSPHL) in the ovarian cancers of NHB patients in comparison to NHW patients [19]. The gene discussed is PSPHP1; the disease is ovarian cancer.